# US 5,858,351 A · Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,858,351 A
- Document ID: US5858351A
- Status: Granted
- Kind: A
- Application number: 08/588,355
- Filed: 1996-01-18
- Granted: 1999-01-12
- Earliest claimed: 1996-01-18
- Assignees: Avigen, Inc.; The Johns Hopkins University
- Inventors: Gregory M. Podsakoff; Paul D. Kessler; Barry J. Byrne; Gary J. Kurtzman
- Web page: https://patentgrep.com/patent/US5858351A

## CPC

- C12N 15/86: Viral vectors
- A61K 38/1816: {Erythropoietin [EPO]}
- A61K 38/47: acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/505: Erythropoietin [EPO]
- C12N 9/2471: {Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase}
- C12Y 302/0102: Alpha-glucosidase (3.2.1.20)
- C12Y 302/01023: Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
- A01K 2217/05: Animals comprising random inserted nucleic acids (transgenic)
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2830/42: being an intron or intervening sequence for splicing and/or stability of RNA
- C12N 2840/44: being a specific part of the splice mechanism, e.g. donor, acceptor
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS

## Abstract

The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of the delivered gene and for in vivo secretion of the therapeutic protein from transduced muscle cells such that systemic delivery is achieved.

## Claims

### Claim 1

A method of expressing a selected gene in muscle cells present in a mammalian subject, said method comprising:
(a) providing recombinant adeno-associated virus (AAV) virions which comprise an AAV vector, said AAV vector comprising said selected gene operably linked to control elements that direct the in vivo transcription and translation of said selected gene in the muscle cells; and
(b) delivering said recombinant AAV virions directly to said muscle cells, whereby said selected gene is expressed at a level which provides a therapeutic effect in the mammalian subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein said muscle cells are derived from skeletal muscle.

### Claim 3 (depends on 1)

The method of claim 1, wherein said muscle cells are derived from smooth muscle.

### Claim 4 (depends on 1)

The method of claim 1, wherein said muscle cells are derived from cardiac muscle.

### Claim 5 (depends on 1)

The method of claim 1, wherein said muscle cells are skeletal myoblasts.

### Claim 6 (depends on 1)

The method of claim 1, wherein said muscle cells are skeletal myocytes.

### Claim 7 (depends on 1)

The method of claim 1, wherein said muscle cells are cardiomyocytes.

### Claim 8 (depends on 1)

The method of claim 1, wherein said selected gene encodes a therapeutic protein.

### Claim 9 (depends on 8)

The method of claim 8, wherein said protein is erythropoietin.

### Claim 10

A method of treating disease in a mammalian subject, said method comprising:
administering directly into muscle of said subject a therapeutically effective amount of a pharmaceutical composition which comprises (a) a pharmaceutically acceptable excipient; and (b) recombinant AAV virions which comprise an AAV vector, said AAV vector comprising a selected gene operably linked to control elements that direct the transcription and translation of said selected gene when present in muscle cells in said subject, whereby said virions transduce muscle cells in said subject, and said selected gene is expressed by said transduced cells at a level sufficient to treat the disease.

### Claim 11

A method of treating disease in a mammalian subject, said method comprising:
(a) introducing recombinant AAV virions into muscle cells in vitro to produce a population of transduced muscle cells, wherein said recombinant AAV virions comprise an AAV vector containing a selected gene operably linked to control elements that direct the transcription and translation of said selected gene when present in said subject; and
(b) administering to muscle of said subject a therapeutically effective amount of a composition comprising a pharmaceutically acceptable excipient and the transduced muscle cells from step (a), whereby said selected gene is expressed by said transduced cells at a level sufficient to treat the disease.

### Claim 12

A method for delivering a therapeutically effective amount of a protein systemically to a mammalian subject, said method comprising:
administering directly into muscle of said subject a pharmaceutical composition which comprises (a) a pharmaceutically acceptable excipient; and (b) recombinant AAV virions which comprise an AAV vector, said AAV vector comprising a selected gene operably linked to control elements that direct the transcription and translation of said selected gene when present in said subject, whereby said virions transduce muscle cells in said subject, and said selected gene is expressed by the transduced cells to produce a systemic level of the protein which provides for a therapeutic effect in said subject.

### Claim 13

A method for delivering a therapeutically effective amount of a protein systemically to a mammalian subject, said method comprising:
(a) introducing recombinant AAV virions into muscle cells in vitro to produce a population of transduced muscle cells, wherein said recombinant AAV virions comprise an AAV vector containing a selected gene operably linked to control elements that direct the transcription and translation of said selected gene when present in said subject; and
(b) administering to muscle of said subject a therapeutically effective amount of a composition comprising a pharmaceutically acceptable excipient and the transduced muscle cells from step (a), whereby said selected gene is expressed by said transduced cells to produce a systemic level of the protein which provides for a therapeutic effect in said subject.

### Claim 14

A method of secreting protein from muscle cells present in a mammalian subject, said method comprising:
(a) providing recombinant adeno-associated virus (AAV) virions which comprise an AAV vector having a gene encoding said protein and operably linked to control elements which direct the in vivo transcription and translation of the gene in said muscle cells; and
(b) delivering the recombinant AAV virion directly to said muscle cells, whereby said protein is expressed and secreted from said muscle cells at a level which provides a therapeutic effect in the mammalian subject.

### Claim 15 (depends on 14)

The method of claim 14, wherein said muscle cells are derived from skeletal muscle.

### Claim 16 (depends on 14)

The method of claim 14, wherein said muscle cells are derived from smooth muscle.

### Claim 17 (depends on 14)

The method of claim 14, wherein said muscle cells are derived from cardiac muscle.

### Claim 18 (depends on 14)

The method of claim 14, wherein said muscle cells are skeletal myoblasts.

### Claim 19 (depends on 14)

The method of claim 14, wherein said muscle cells are skeletal myocytes.

### Claim 20 (depends on 14)

The method of claim 14, wherein said muscle cells are cardiomyocytes.

### Claim 21 (depends on 14)

The method of claim 14, wherein said recombinant AAV virions are delivered in vivo.

### Claim 22 (depends on 21)

The method of claim 21, wherein said recombinant AAV virions are delivered by intramuscular injection.

### Claim 23 (depends on 14)

The method of claim 14, wherein said recombinant AAV virions are delivered to said muscle cells in vitro and said muscle cells are delivered directly into muscle of said subject.

### Claim 24 (depends on 14)

The method of claim 14, wherein the protein is a therapeutic protein.

### Claim 25 (depends on 24)

The method of claim 24, wherein said protein is acid .alpha.-glucosidase.
